{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:52:58Z","timestamp":1792792378129,"version":"4.5.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"13","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck Healthcare Germany GmbH, Weiterstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","award":["10.13039\/100009945"],"award-info":[{"award-number":["10.13039\/100009945"]}],"id":[{"id":"https:\/\/ror.org\/047693029","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2022,9,2]]},"DOI":"10.1080\/14656566.2022.2106783","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T13:34:44Z","timestamp":1659706484000},"page":"1503-1510","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":30,"title":["Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-3501","authenticated-orcid":false,"given":"Sven G","family":"Meuth","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Neurologie des Universit\u00e4tsklinikums D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7418-9040","authenticated-orcid":false,"given":"Antonios","family":"Bayas","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie und Klinische Neurophysiologie, Medizinische Fakult\u00e4t, Universit\u00e4t Augsburg, Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Kallmann","sequence":"additional","affiliation":[{"name":"Multiple Sklerose Zentrum Bamberg, Bamberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8740-3106","authenticated-orcid":false,"given":"Ralf","family":"Linker","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Neurologie, Universit\u00e4tsklinikum Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6921-0135","authenticated-orcid":false,"given":"Peter","family":"Rieckmann","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Neurologie, Medical Park Loipl, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-2897","authenticated-orcid":false,"given":"Mike P","family":"Wattjes","sequence":"additional","affiliation":[{"name":"Department of diagnostic and interventional Neuroradiology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"M\u00e4urer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie, Juliusspital W\u00fcrzburg Klinikum W\u00fcrzburg Mitte gGmbH, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1650-8875","authenticated-orcid":false,"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie, Universit\u00e4tsklinikum Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"cit0001","unstructured":"EMA summary of product charateristics: mavenclad\u00ae (cladribine tablets) [cited 2022 Mar 7]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf."},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510391344"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.021"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322326"},{"issue":"15","key":"cit0007","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1212\/WNL.96.15_supplement.1919","volume":"96","author":"Giovannoni G","year":"2021","journal-title":"Neurology"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102572"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517726380"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103385"},{"key":"cit0011","volume-title":"Poster presentation P0849 presented at: MS Virtual Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS)","author":"Penner IK","year":"2020"},{"key":"cit0012","volume-title":"Poster presentation P859 presented at: European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","author":"Ziemssen T","year":"2021"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92826-2"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.754012"},{"issue":"15","key":"cit0015","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1212\/WNL.96.15_supplement.2235","volume":"96","author":"Wiendl H","year":"2021","journal-title":"Neurology"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001187"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2004.00259.x"},{"issue":"1","key":"cit0018","first-page":"93","volume":"7","author":"Janiec K","year":"2001","journal-title":"Med Sci Monit"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02433.x"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2011.09.010"},{"issue":"3","key":"cit0021","first-page":"225","volume":"60","author":"Niezgoda A","year":"2001","journal-title":"Folia Morphol (Warsz)"},{"issue":"15","key":"cit0022","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1212\/WNL.94.15_supplement.4347","volume":"94","author":"Strazielle N","year":"2020","journal-title":"Neurology"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-018-0498-0"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6775-0"},{"key":"cit0025","unstructured":"Giovannoni G, Berger J, Leist T, et al. Post-Approval safety of cladribine tablets with particular reference to COVID-19 outcomes: an update. ECTRIMS Vienna 2021."},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1792885"},{"key":"cit0027","unstructured":"Giovannoni G, Leist T, Aydemir A, et al. Classic-MS: long-term efficacy and real-world treatment patterns for patients receiving cladribine tablets - interim data with 8\u201314 years follow-up. Multiple Sclerosis Journal. 2020;Vol. 26:LB1229. S3."},{"key":"cit0028","unstructured":"European Medicines Agency Assessment Report, cladribine tablets (Mavenclad), June 2017 [cited 2022 Mar 18]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/mavenclad-epar-public-assessment-report_en.pdf"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420922685"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103075"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1177\/11795735211060118"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103863"},{"key":"cit0033","volume-title":"Poster presentation EP1593 presented at: ECTRIMS","author":"Lyons M","year":"2019"},{"key":"cit0034","first-page":"189624","volume":"2013","author":"Healy BC","year":"2013","journal-title":"Mult Scler Int"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.108"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz144"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211028561"},{"issue":"1","key":"cit0039","first-page":"629","volume":"29","author":"Ellenberger D","year":"2022","journal-title":"Eur J Neurol"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211012227"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103755"},{"key":"cit0042","unstructured":"KKNMS. Quality Handbook MS\/NMOSD. Recommendations for the treatment of multiple sclerosis\/neuromyelitis-optica-diseases for physicians. [Qualit\u00e4tshandbuch MS\/NMOSD. Empfehlungen zur Therapie der Multiple Sklerose\/Neuromyelitis-optica-Spektrum-Erkrankungen f\u00fcr \u00c4rzte]. 5. revised and updated edition January 2020 [cited 2021 May 3]. Available from: http:\/\/www.kompetenznetz-multiplesklerose.de."},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00339-7"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215207"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab241"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2011.08.001"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1568"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2022.2106783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T17:08:34Z","timestamp":1727716114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2022.2106783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":47,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,9,2]]}},"alternative-id":["10.1080\/14656566.2022.2106783"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2022.2106783","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}